Bibliografía Comentada

Fernando Rivera Herrero

Responsable de la sección
Hospital Universitario Marqués de
Valdecilla

Esta sección está supervisada por el grupo de expertos de Oncobyg. La información recogida en esta web refleja únicamente la opinión del grupo de expertos de Oncobyg, y sus recomendaciones no pretenden sustituir a las directrices de consensos de sociedades médicas o de las guías de tratamiento oncológico vigentes en la actualidad

Cáncer gástrico

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer

Eunice Lee Kwak, Patricia LoRusso, Omid Hamid, et al. J Clin Oncol 33, 2015 (suppl 3; abstr 1)

25 de enero de 2016


METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC)

Manish A. Shah, Yung-Jue Bang, Florian Lordick, Josep Tabernero, Meng Chen, et al. J Clin Oncol 33, 2015 (suppl; abstr 4012)

25 de enero de 2016


Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC)

Manish A. Shah, Jae Yong Cho, Iain Tan Bee Huat, et al. J Clin Oncol 33, 2015 (suppl 3; abstr 2)

25 de enero de 2016


Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study

David Cunningham, Niall C. Tebbutt, Irina Davidenko, André M. Murad, Salah-Eddin Al-Batran, et al. J Clin Oncol 33, 2015 (suppl; abstr 4000).

25 de enero de 2016


A phase Ib study of Pembrolizumab in patients with advanced gastric cancer

K Muro, Y Bang, V Shankaran et al. Annals of Oncology (2014) 25 (5): 1-41.

25 de enero de 2016


Comprehensive molecular characterization of gastric adenocarcinoma

Cancer Genome Atlas Research Network. Nature. 2014 Sep 11;513(7517):202-9.

25 de enero de 2016


Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

Cho EY, Park K, Do I, Cho J, et al. Mod Pathol. 2013 May;26(5):677-84.

9 de febrero de 2015


Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis

Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, Ge S, Shen L.  PLoS One. 2014 Jan 8;9(1):e84502. doi: 10.1371/journal.pone.0084502. eCollection 2014.

9 de febrero de 2015


Clinical significance of SPARC gene expression in patients with gastric cancer.

Sato T, Oshima T, Yamamoto N, Yamada T, et al.

8 de diciembre de 2013


Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.

Wang JL, Hu Y, Kong X,et al.

9 de diciembre de 2013


A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.

Yung-Jue Bang

9 de diciembre de 2013


Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

J. Randolph Hecht, Yung-Jue Bang, Shukui Qin, et al.

4 de diciembre de 2013


Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

Carlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.

15 de diciembre de 2013